ClinicalTrials.Veeva

Menu

Drug-Drug Interaction Study With Aricept® (Donepezil)

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 1

Conditions

Alzheimer Disease

Treatments

Drug: BMS-708163
Drug: Donepezil

Study type

Interventional

Funder types

Industry

Identifiers

NCT01042314
CN156-008

Details and patient eligibility

About

The purpose of this study is to find out if the plasma concentration of donepezil is changed when BMS-708163 is administered at the same time

Enrollment

18 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Healthy men and postmenopausal women

Exclusion criteria

  • Medical History and Concurrent Diseases
  • Gastrointestinal disease
  • Gastrointestinal bleeding disorders
  • History of peptic ulcer disease
  • History of cholecystectomy
  • History of seizure disorder
  • History of asthma
  • History of Chronic Obstructive Pulmonary Disease
  • History of cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes
  • Inability to tolerate oral medication
  • Inability to be venipunctured and/or tolerate venous access

Trial design

18 participants in 1 patient group

Donepezil and BMS-708163
Experimental group
Treatment:
Drug: Donepezil
Drug: BMS-708163

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems